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Background: Indacaterol is an inhaled, once-daily long-acting β2-agonist bronchodilator for 
regular use in patients with chronic obstructive pulmonary disease (COPD). As indacaterol 
is the first once-daily β2-agonist to be developed, it is relevant to evaluate its bronchodilator 
efficacy, safety, and tolerability.
Methods: Data were pooled from three randomized, double-blind, clinical studies in patients 
with moderate-to-severe COPD treated with indacaterol 150 µg qd (n = 627) or placebo 
(n = 1021). Bronchodilator efficacy was assessed as trough (24-hour post-dose) forced expira-
tory volume in 1 second (FEV1) after 12 weeks (primary endpoint in individual studies) and 
FEV1 measured serially post-dose. Rescue use of albuterol was monitored.
Results: At week 12, indacaterol increased trough FEV1 by 160 mL compared with placebo 
(P , 0.001), exceeding the 120 mL level prespecified as clinically important. FEV1 during the 
first 12-hour post-dose at week 12 averaged 210 mL higher with indacaterol than with placebo 
(P , 0.001). Patients receiving indacaterol recorded 53% of days without use of rescue albuterol, 
compared with 38% of days in the placebo group (P , 0.001). Adverse events (mostly mild 
or moderate) were reported for 52% and 46% of patients receiving indacaterol and placebo, 
respectively, and serious adverse events for 4% and 5%. Worsening of COPD was the most 
frequent adverse event (10% indacaterol; 15% placebo). Indacaterol had little effect on pulse or 
blood pressure or measures of systemic β2-adrenoceptor activity (blood glucose, serum potas-
sium, and corrected QT interval).
Conclusion: Indacaterol was an effective bronchodilator and was well tolerated, with a good 
safety profile over 12 weeks of treatment. It should prove a useful treatment for patients with 
moderate-to-severe COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is an obstructive pulmonary disease 
characterized by progressive resting and exertional dyspnea and is associated with 
major comorbidities.1 In 2005, approximately 1 in 20 deaths in the United States was 
caused by COPD,2 and COPD was reported to affect an estimated 6% of US adults 
in 2008,3 with higher prevalence figures in higher-risk groups such as veterans (9%) 
and Medicare beneficiaries (11%).4,5 However, COPD is often underdiagnosed and is 
relatively undertreated compared with other, less morbid, chronic conditions such as 
hypertension and hypercholesterolemia.6
According to current guidelines for the treatment of stable COPD, the regular use of 
long-acting bronchodilators is recommended for initial maintenance treatment of COPD.1 International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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These agents are either β2-agonists administered twice daily 
(formoterol and salmeterol) or the once-daily anticholinergic, 
tiotropium. In the management of stable COPD, bronchodila-
tor treatment improves forced expiratory volume in 1 second 
(FEV1) with a concomitant reduction in hyperinflation, and 
reduction in symptoms such as breathlessness (dyspnea).7
Indacaterol is a novel, inhaled, long-acting β2-agonist 
providing 24-hour bronchodilation on once-daily dosing,8–10 
currently approved in many countries for the maintenance 
treatment of COPD. The purpose of this manuscript, using 
data pooled from the indacaterol clinical trial database, is to 
provide a comprehensive evaluation of the bronchodilator 
efficacy, safety, and tolerability of indacaterol 150 µg com-
pared with placebo in a large sample of patients with COPD. 
The 150 µg dose was identified in the dose-ranging stage of 
a Phase II/III adaptive seamless design study as the lowest 
dose of indacaterol providing effective bronchodilation in 
COPD.11 The data presented represent the results from the 
first 12 weeks of dosing in three   registration studies with iden-
tical patient entry criteria. The 150 µg dose of indacaterol was 
evaluated in two of the studies; only data from the placebo 
group in the third study (which assessed higher indacaterol 
doses) are included in the pooled dataset. All three studies 
are the subject of separate publications.8–10
Methods
The study designs are described in detail in the individual 
publications.8–10 All were randomized, double-blind, parallel-
group comparisons of indacaterol and placebo prescribed 
once daily. One was a 12-week comparison of indacaterol 
150 µg and placebo;8 one was a 6-month comparison of 
indacaterol 150 µg and placebo (and indacaterol 300 µg and 
tiotropium; not reported here)10 and the third study, which 
contributed placebo data only to the present analysis, was a 
comparison of indacaterol 300 and 600 µg qd, formoterol, and 
placebo.9 Indacaterol 150 µg and placebo were administered 
using identical single-dose dry-powder inhalers and were 
used daily each morning. All study protocols were approved 
by the independent ethics committee or institutional review 
board for each participating center. All patients provided 
written informed consent prior to participation.
The studies recruited patients aged $40 years with 
moderate-to-severe COPD and a smoking history of $20 
pack-years. Patients had relatively stable COPD, and were 
excluded if they had a recent chest infection or had recently 
been hospitalized for a COPD exacerbation.
Other bronchodilator treatments were discontinued 
before the start of study treatment, apart from albuterol, 
which patients could use as required. Patients were allowed 
to continue treatment with inhaled corticosteroids (ICS) 
during the study, providing they were using ICS at the time 
of screening; the dose and regimen were not altered for the 
duration of the study. Treatment with combination ICS and 
bronchodilators was replaced with the ICS component alone, 
at equivalent dose and regimen.
Spirometry was performed at screening, at baseline, and 
at regular clinic visits during the studies, according to recog-
nized standards.12 The primary efficacy outcome in each study 
was FEV1 measured at ‘trough’ (the mean of measurements 
taken at 23 hours and 10 minutes and 23 hours and 45 minutes 
post-dose) after 12 weeks of treatment. In each study, a dif-
ference between indacaterol and placebo of 120 mL in FEV1 
was prespecified as a minimal clinically important difference. 
Spirometry was also performed at serial time points post-dose 
at clinic visits, including those at baseline and week 12. The 
patients’ use of albuterol as rescue medication, recorded on 
daily diary cards, was a secondary efficacy outcome.
A secondary objective of the studies was to assess 
safety, including adverse events, electrocardiograms (ECGs) 
  (measurement of corrected QT [QTc] interval), laboratory 
tests (measurement of blood glucose and serum potassium 
concentrations), and vital signs (blood pressure and pulse rate) 
measured at baseline and pre- and post-dose at week 12.
Statistical methods
The methodology used for pooling the data was to include all 
available data from studies that were designed with identical 
or near-identical methods and patient entry criteria. Hence, 
data from the placebo treatment group of a study investi-
gating higher doses of indacaterol (300 and 600 µg qd)9 
were included in the pooled dataset. The primary endpoint, 
trough FEV1, was analyzed using a mixed-model analysis of 
covariance (ANCOVA) with treatment as a fixed effect, and 
baseline FEV1 and FEV1 reversibility as covariates. Smoking 
status (current/ex-smoker), country, and study were included 
as fixed effects, and center nested within country as a random 
effect. Estimates of adjusted treatment effects and pairwise 
treatment differences from the ANCOVA are presented along 
with the associated 95% confidence intervals (CIs) and two-
sided P-values. The percentage of days with no rescue use 
during the 12 weeks and the standardized area under the curve 
for FEV1 at week 12 (measured from 5 minutes to 11 hours 
and 45 minutes post-dose) were analyzed using the same 
mixed model, with the appropriate baseline measurement 
as covariates. No adjustment was made for multiple testing 
for the pooled analyses.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Results
Table 1 shows the patients’ demographic and clinical 
  characteristics. Apart from a slightly higher proportion of 
men compared with women in the placebo group, the two 
treatment groups were well matched. Baseline prebroncho-
dilator percent predicted FEV1 was 49% in both treatment 
groups; post-bronchodilator (albuterol) values were also 
similar in the two groups (indacaterol 56%; placebo 55% 
predicted).
Efficacy
Spirometry
Trough FEV1 (24 hours post-dose) was significantly higher 
with indacaterol compared with placebo both after the first 
dose and at week 12 (both P , 0.001) (Figure 1). The dif-
ference of 160 mL at week 12 was one-third greater than 
the prespecified difference of minimal clinical importance 
(120 mL). After the first dose, trough FEV1 was 100 mL 
greater with indacaterol than with placebo.
In terms of mean changes from baseline, the effects of 
indacaterol on trough FEV1 equated to 130 mL (9.7%) after 
the first dose, and 150 mL (11.4%) at week 12 (Figure 2). 
Corresponding values with placebo treatment were 20 mL 
(1.5%) after the first dose and 10 mL (0.8%) at week 12.
Serial post-dose measurements of FEV1 after the first 
dose and at week 12 are shown in Figure 3. The analysis 
of the standardized area under the curve showed that FEV1 
was on average 210 mL (95% CI 150–280 mL) higher with 
indacaterol than with placebo during the first 12 hours post-
dose (P , 0.001).
Table 1 Patient characteristics at baseline
Indacaterol 150 μg  
N = 627
Placebo  
N = 1021
Age, years 63.2 (9.56) 63.6 (8.69)
Age $65 years, % 47 46
Sex, male/female, % 58/41 67/33
COPD severity, %
  Moderate or less
  Severe or worse
 
61
39
 
59
41
Duration of COPD, years 6.8 (7.09) 6.8 (6.15)
ICS use, % 35 44
Smoking history
  Ex-/current smoker, %
  Pack-years
 
53/47
50.0 (24.72)
 
55/45
50.6 (32.33)
FEV1 pre-albuterol, L 1.33 (0.497) 1.35 (0.478)
FEV1 pre-albuterol, %  
predicted
49.0 (14.54) 48.8 (13.99)
FEV1 post-albuterol, La 1.51 (0.510) 1.52 (0.497)
FEV1 post-albuterol, %  
predicteda
55.5 (14.13) 55.0 (14.15)
FEV1/FVC post-albuterola 0.53 (0.099) 0.53 (0.104)
FEV1 reversibility, %b 15.9 (16.07) 14.8 (16.51)
Notes: Data are mean (standard deviation) unless otherwise stated. aPost-albuterol 
measurements taken 30 minutes after patients inhaled albuterol 380 µg (four puffs); 
bReversibility calculated as difference between pre- and post-albuterol values divided 
by the pre-albuterol value, expressed as a percentage.
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  FEV1,  forced 
expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroids.
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Figure  1  Trough  forced  expiratory  volume  in  1  second:  differences  between 
indacaterol and placebo treatment after first dose (measured on day 2) and after 
12 weeks’ treatment. Broken line indicates prespecified level of clinical importance.
Notes: Data are least squares means and 95% confidence intervals. ***Denotes 
P , 0.001 vs placebo.
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Figure 2 Trough FEV1 after the first dose (day 2) and after 12 weeks of treatment, 
expressed as change from baseline (absolute (A) and percentage (B)). 
Note: Data are unadjusted means ± standard error.
Abbreviation: FEV1, forced expiratory volume in 1 second.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Figure 4 illustrates the bronchodilator effect of   treatment 
during the first hour following dosing on day 1. FEV1 was 
significantly higher following indacaterol compared with 
placebo at each time point (P , 0.001), with differences 
of 120 mL (5 minutes post-dose) and 150 mL (30 and 
60 minutes post-dose).
Forced vital capacity (FVC) during treatment was 
evaluated in only one of the studies comparing indacaterol 
150 µg qd with placebo.10 Results after 12 weeks of   treatment 
are shown in Figure 5,10 demonstrating that indacaterol 
significantly increased FVC compared with placebo at each 
time point post-dose (P , 0.001).
Days without use of rescue albuterol
Patients treated with indacaterol recorded no use of rescue 
albuterol on 52.7% of days, a 40% increase compared 
with the 37.7% rescue-free days among the placebo group 
(Figure 6).
Safety
Adverse events
The incidence of (percentage of patients with) adverse 
events is shown in Table 2. In most cases (indacaterol 88%; 
placebo 87%), the adverse events were mild or moderate in 
severity. Comparing the two treatment groups, upper respi-
ratory tract infection, headache, and muscle spasms were 
reported more frequently with indacaterol treatment than 
with placebo. For upper respiratory tract infection, all but 
one of the 33 cases (97%) during indacaterol treatment were 
mild or moderate, and none was considered to be related 
to the study drug. With indacaterol, headache was mild or 
moderate in most patients (26/28; 93%), and was considered 
related to the study drug in six patients (21%). The episodes 
of muscle spasms with indacaterol were generally mild or 
moderate (13/18; 72%), and were considered related to the 
study drug in six patients (33%). Only one of these cases 
(the episode of severe upper respiratory tract infection) was 
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Figure 3 FEV1 measured at serial time points post-dose on day 1 and week 12. 
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classed as a serious adverse event. Other events associated 
with β2-agonist treatment were uncommon. Tremor occurred 
in one patient (0.16%) receiving indacaterol and in five 
receiving placebo (0.47%). Tachycardia was reported for 
five patients (0.80%) receiving indacaterol and five (0.47%) 
receiving placebo.
Overall, serious adverse events occurred in 33 (3.9%) 
and 47 (4.5%) of patients receiving indacaterol and placebo, 
respectively. The most common serious adverse event was 
“COPD worsening” (which includes disease progression 
and COPD exacerbations) (indacaterol, 0.6% of patients; 
placebo, 1.6% of patients). Two patients died during the 
3-month treatment period, and both of them were in the 
placebo group.
The incidence of abnormal values for blood chemistries, 
vital signs, and ECG (QTc interval) is shown in Table 3. The 
one patient with a QTc interval . 500 milliseconds also had 
a high baseline value (515 milliseconds) and a history of 
cardiac insufficiency, and was being treated with amiodarone, 
an anti-arrhythmic known to prolong QTc interval.
Discussion
The studies that comprised the data for this analysis had 
identical entry criteria and followed the same methodologies. 
Despite their differing durations, the three studies shared 
a common primary efficacy outcome that was assessed at 
the same 12-week time point. The pooled dataset used here 
therefore provides a much larger database to report on the 
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Table 2 Adverse events overall and most commonly occurring   
($2% of indacaterol treatment group) (3-month safety population)
Indacaterol 150 μg (%)  
N = 627
Placebo (%)  
N = 1055
Patients with $1  
adverse event
51.7 46.3
  COPD worsening 10.2 15.1
  Cough 5.3 4.3
    Upper respiratory  
tract infection
5.3 2.6
  Nasopharyngitis 4.8 5.8
  Headache 4.5 2.6
  Muscle spasms 2.9 1.1
  Diarrhea 2.4 1.5
  Dyspnea 2.2 2.7
  Back pain 2.1 1.7
  Bronchitis 2.1 2.4
  Dizziness 1.9 1.6
  Nausea 1.9 1.4
    Lower respiratory  
tract infection
1.8 2.2
  Pharyngolaryngeal pain 1.8 0.8
  Sinusitis 1.8 0.8
  Urinary tract infection 1.8 1.2
    Viral upper respiratory  
tract infection
1.6 1.5
  Arthralgia 1.3 0.7
  Influenza 1.3 0.8
  Edema peripheral 1.1 0.4
Abbreviation: COPD, chronic obstructive pulmonary disease.
Table 3 Incidence of clinically notable values for blood glucose, 
serum potassium, blood pressure, pulse rate and QTc interval, 
recorded at any time post-baseline (3-month safety population)
Indacaterol 150 μg   
n (%)  
N = 627
Placebo  
n (%)  
N = 1055
Blood glucose .9.99 mmol/L  
(179.8 mg/dL)
34 (5.4) 49 (4.7)
Serum potassium ,3 mmol/L 0 3 (0.3)
Systolic blood pressure  
  Lowa  
  Highb
1 (0.19)  
4 (0.64)
13 (1.23)  
15 (1.42)
Diastolic blood pressure  
  Lowc  
  Highd
4 (0.64)  
5 (0.80)
7 (0.66)  
12 (1.14)
Pulse rate  
  Lowe  
  Highf
4 (0.64)  
0
15 (1.42)  
5 (0.47)
QTc intervalg absolute value 
  .450 (M) or .470 (F) ms  
  .500 ms
20 (3.2)  
1 (0.2)
33 (3.1)  
0
QTc intervalg increase  from baseline  
  30–60 ms  
  .60 ms
48 (7.7)  
0
59 (5.7)  
1 (0.1)
Notes:  a,75 mmHg, or #90 and decrease from baseline of $20 mmHg;  b.200 mmHg, 
or $180 and increase from baseline of $20 mmHg; c,40 mmHg, or #50 and decrease 
from baseline of $15 mmHg;  d.115 mmHg, or $105 mmHg and increase from baseline 
of $15 mmHg; e,40 bpm, or #50 bpm and decrease from baseline of $15 bpm;   
f$120 bpm and increase from baseline of $15 bpm, or .130 bpm; gCalculated using 
Fridericia’s formula.
Abbreviation: QTc, corrected QT interval.
Figure 6 Percentage of days with no use of rescue albuterol over 3 months of   
treatment.
Notes: Data are least squares means ± standard error. ***Denotes P , 0.001 vs placebo.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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efficacy, tolerability, and safety of indacaterol 150 µg qd. 
Once-daily dosing with indacaterol 150 µg provided a 
bronchodilator effect at 24 hours post-dose (trough FEV1) 
that was 160 mL greater than with placebo. This level of 
bronchodilation exceeded the 120 mL difference prespeci-
fied in the clinical studies as denoting clinical importance, 
and is also in excess of the 100–140 mL range that has been 
reported to be clinically significant in patients with COPD.13 
The bronchodilator effect of indacaterol on trough FEV1 
after the first dose was 100 mL greater than that observed 
with placebo.
Circadian variation in lung function is a normal process 
that also occurs in obstructive airway diseases, including 
COPD, and results in the lowest FEV1 levels in the early hours 
of the morning.14–17 In COPD, the normal early-morning 
decrease in FEV1 is thought to be increased by the airflow 
obstruction in this disease and may be worsened by increased 
morning sputum production.18 Reduced β2-adrenergic recep-
tor stimulation due to decreased levels of endogenous cat-
echolamines has also been proposed as a contributing factor.19 
It is therefore important to provide effective bronchodilation 
over the entire day, especially during the early morning. 
Treatment with a long-acting β2-agonist bronchodilator 
may represent an appropriate therapeutic approach. The 
early morning is also the time of day when symptoms are 
worse or the worst, and shortness of breath is often limiting 
for the patient’s routine and daily activities in life.20 Trough 
FEV1 is a measure of early-morning efficacy of a long-acting 
β2-agonist, and the excellent bronchodilation still provided 
by indacaterol at this critical time of day may be helpful to 
COPD patients, facilitating improved levels of activity and 
resulting in improved quality of life.
The 160 mL difference in week 12 trough FEV1 with 
indacaterol compared with placebo is similar or slightly 
better than previous reports of the effect of tiotropium in 
placebo-controlled studies (difference of 120–137 mL in 
trough FEV1 for tiotropium compared with placebo).21–24 
Reported differences in trough FEV1 between tiotropium 
and the twice-daily β2-agonist salmeterol are approximately 
20–50 mL in favor of tiotropium.22,24,25 Thus, indacaterol 
appears to have a greater effect on trough FEV1 than other 
available long-acting bronchodilator treatments for COPD. 
The bronchodilator efficacy of indacaterol increased from 
the first dose to the measurements performed at the end of 
12 weeks of treatment. In longer-term studies, the efficacy of 
indacaterol 150 µg qd was not reduced with repeated dosing 
for 6 or 12 months, showing persistence of bronchodilator 
response without tachyphylaxis.10,26,27 In contrast, a decline 
in bronchodilator effectiveness over time has been reported 
with both the twice-daily β2-agonists.28,29
The bronchodilator effect of indacaterol was also demon-
strated in terms of its improvement of FVC. Effects on FVC 
generally reflect effects on FEV1 but can also be useful in 
patients with COPD, specifically those with hyperinflation, 
to identify a therapeutic response in the absence of effects 
on FEV1.13 This reduction in hyperinflation may represent 
an important mechanism through which indacaterol reduces 
symptoms in COPD.
A very important finding of this analysis is that treatment 
with indacaterol showed improvement in disease control, 
since the bronchodilation provided by indacaterol occurred 
in association with a 40% increase in rescue-free days 
compared with placebo. This reduction in the requirements 
for albuterol use for symptom relief suggests that patients 
receiving indacaterol were experiencing reduced symptoms.30 
Extrapolated to longer-term use, the difference in rescue 
use between treatments equates to 55 more days per year 
in which patients with moderate-to-severe COPD did not 
use albuterol while taking indacaterol, compared with those 
treated with a placebo.
While comparisons with placebo are a necessary step for 
approval of new treatments, it is relevant for practicing clini-
cians to judge the efficacy of a new treatment against other 
agents that are available for the treatment of COPD patients. 
Direct comparisons with other long-acting bronchodilators 
have been published recently. They show that indacaterol 
150 µg qd had a bronchodilator effect similar to that of 
the once-daily anticholinergic, tiotropium, while providing 
greater improvements in symptoms and health status.31 In 
comparison with the twice-daily β2-agonist, salmeterol, 
indacaterol proved to be a superior bronchodilator and had a 
greater effect in reducing dyspnea even though indacaterol-
treated patients used less rescue medication.32
The overall frequency of adverse events and serious 
adverse events was similar between active and placebo treat-
ments in the present analysis. The most common adverse 
event, “COPD worsening,” occurred more often in the pla-
cebo group, which suggests a potential beneficial effect of 
indacaterol on COPD exacerbations. Those adverse events 
occurring more frequently with indacaterol were mostly mild 
or moderate, and indacaterol was well tolerated. The side 
effects of tremor and tachycardia that would be expected to 
result from β2-adrenergic stimulation were less common with 
indacaterol than with placebo. Muscle spasms were more 
common with indacaterol than with placebo (2.9% vs 1.1%), 
but these events were generally mild or moderate in   severity. International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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The incidence of changes in glucose and potassium, and 
prolongation of QTc interval, were very low and similar with 
indacaterol and placebo treatments. Thus, in a large analysis 
of patients with COPD, therapy with indacaterol was well 
tolerated with a side-effect profile similar to placebo.
Adherence with treatment is often poor among patients 
with chronic respiratory diseases, including COPD.33–35 
Adherence in chronic diseases is reported to be inversely 
related to the number of doses per day, and poor adher-
ence may contribute to the poor control of many medical 
disorders.36 Once-daily dosing provides a simplified dosing 
regimen that should improve adherence and ensure more 
persistent medication use.37,38 Thus, the development of an 
effective treatment for COPD with a simplified treatment 
regimen (eg, infrequent dosing, simple delivery), rapid 
onset of action and durable effect should improve patient 
adherence.39
Conclusion
Consistent with international evidence-based treatment 
guidelines, the COPD patients included in the present analy-
sis are appropriate candidates for regular maintenance treat-
ment with one or more long-acting bronchodilators.1,7 In view 
of its efficacy and the safety profile described in this report, 
once-daily indacaterol represents an appropriate treatment 
for patients with moderate-to-severe COPD.
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